All In Biotech

Drug Trial Radar · NCT03521934

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure

Last checked: Nov 20, 2026Latest source record: Oct 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,222 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,222

Actual

Start

Jun 15, 2018

Primary completion

Jun 5, 2020

Study completion Jun 5, 2020

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Sanofi
First posted
May 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To compare the effect of sotagliflozin to placebo on the total occurrences of cardiovascular (CV) death, hospitalization for heart failure (HHF), and urgent visit for heart failure (HF) in hemodynamically stable participants after admission for worsening heart failure (WHF) Secondary Objectives: To compare the effects of sotagliflozin to placebo on: * The total occurrences of HHF and urgent visit for HF * The occurrence of CV death * The occurrence of all-cause mortality * The total occurrences of CV death, HHF, urgent visit for HF, non-fatal myocardial infarction (MI), and non-fatal stroke * Change in Kansas City Cardiomyopathy Questionnaire-12(KCCQ-12) score * Change in estimated glomerular filtration rate (eGFR)

Conditions

  • Heart Failure
  • Type 2 Diabetes Mellitus

Interventions

  • SotagliflozinDrug

    Pharmaceutical form: tablet Route of administration: oral

  • PlaceboDrug

    Pharmaceutical form: tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)Time frame: Up to 21.9 months

Locations

466 sites in 32 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8400128

    Alexander City, Alabama

  • Investigational Site Number 8400109

    Cottonwood, Arizona

  • Investigational Site Number 8400032

    Little Rock, Arkansas

  • Investigational Site Number 8400080

    Little Rock, Arkansas

  • Investigational Site Number 8400075

    Bakersfield, California

  • Investigational Site Number 8400069

    Fresno, California

  • Investigational Site Number 8400008

    Los Angeles, California

  • Investigational Site Number 8400063

    Los Angeles, California

  • Investigational Site Number 8400127

    National City, California

  • Investigational Site Number 8400007

    Redondo Beach, California

  • Investigational Site Number 8400036

    Stockton, California

  • Investigational Site Number 8400033

    Sylmar, California

  • Investigational Site Number 8400049

    Torrance, California

  • Investigational Site Number 8400028

    Walnut Creek, California

  • Investigational Site Number 8400029

    Bridgeport, Connecticut

  • Investigational Site Number 8400037

    New Haven, Connecticut

  • Investigational Site Number 8400046

    DeLand, Florida

  • Investigational Site Number 8400009

    Gainesville, Florida

  • Investigational Site Number 8400079

    Homestead, Florida

  • Investigational Site Number 8400031

    Jacksonville, Florida

  • Investigational Site Number 8400022

    Jacksonville, Florida

  • Investigational Site Number 8400098

    Lake Mary, Florida

  • Investigational Site Number 8400058

    Miami Beach, Florida

  • Investigational Site Number 8400105

    Orlando, Florida

  • Investigational Site Number 8400082

    Pensacola, Florida

  • Investigational Site Number 8400057

    Port Charlotte, Florida

  • Investigational Site Number 8400006

    Sarasota, Florida

  • Investigational Site Number 8400035

    Tampa, Florida

  • Investigational Site Number 8400042

    Tampa, Florida

  • Investigational Site Number 8400004

    Wellington, Florida

  • Investigational Site Number 8400073

    Atlanta, Georgia

  • Investigational Site Number 8400118

    Tucker, Georgia

  • Investigational Site Number 8400067

    Arlington Heights, Illinois

  • Investigational Site Number 8400043

    Chicago, Illinois

  • Investigational Site Number 8400072

    Elk Grove Village, Illinois

  • Investigational Site Number 8400055

    Indianapolis, Indiana

  • Investigational Site Number 8400020

    Muncie, Indiana

  • Investigational Site Number 8400122

    Richmond, Indiana

  • Investigational Site Number 8400091

    Waterloo, Iowa

  • Investigational Site Number 8400030

    Covington, Louisiana

Showing 40 of 466 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.